Evaxion’s EVX-01 Phase 2 Trial Shows 92% Of Melanoma Patients Still Responding At Two Years With No Relapses, And All Responses Maintained At Three Years Without Progression
Share
Why It Matters
A medicine test showed most patients stayed healthy for years. When you see long term results like this, watch if the company moves closer to selling it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.